Eli Lilly and Company LLY will report its fourth-quarter and full-year 2024 earnings on Feb. 6, before market open. The Zacks ...

Novo Nordisk today announced 2024 earnings, reporting a 26% increase in annual sales to ~$40.56bn. Read why I upgrade NVO ...

Novo Nordisk has a dominant position in diabetes and weight-loss drugs, strong financial growth outlook, and great potential. Click to read why NVO is a Strong Buy.

Novo Nordisk NVO is scheduled to report fourth-quarter 2024 results on Feb. 5, 2025, before the opening bell. The Zacks ...

Eli Lilly (NYSE: LLY) has underperformed broader equities. While that's not much of an issue in the grand scheme of things, it is still a bit surprising, since the pharmaceutical giant is one of the ...

Metsera and Maze Therapeutics have become the second and third biotechs to complete an initial public offering (IPO) on the ...

If your weight loss goals have taken a backward step, this simple device might be all you need to get back on track and shed some stones ...

We recently compiled a list of the 12 Best Big Name Stocks to Invest in Now. In this article, we are going to take a look at ...

Those too slim to be eligible for injections can no longer get prescription without seeing a doctor under new guidance ...

With new drug development, a significant increase in sales, and high potential with Mounjaro and Zepbound, here’s what we think of Eli Lilly’s stock ...

Ensure you can keep your favorite music forever with our list of the best places to buy MP3s and FLAC files. Ty Pendlebury has worked at CNET since 2006. He lives in New York City where he writes ...

Obesity medication prescriptions reached 1.5 million, driven by GLP-1 agents semaglutide and tirzepatide, as public interest ...